Risk Assessment Strategy / Tools & Technology

Topic	Replies	Views	Activity
Carcinogenic Potency Database - Access free With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…	3	1500	August 22, 2022
About the Risk Assessment Strategy / Tools & Technology category	0	503	April 14, 2021
Risk Analysis for Ergotamine Tartrate Drug_Substance_APIs	4	217	April 22, 2024
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day	26	3287	April 2, 2024
Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process -Pub NDSRI , featured	1	641	February 6, 2024
Application of duplex sequencing to evaluate mutagenicity -Pub NDSRI	1	194	March 14, 2024
Nitrosamines evaluation in transdermal patches featured	10	1308	March 5, 2024
Regulatory Highlights(OPR&D)	14	1674	February 28, 2024
Is it possible to observe N-nitrosamines formation from oximes? Do you have any reference to support the risk assessment for nitrosamine formation from the reaction of these functional groups in the presence of nitrosating agents? Thank you NDSRI	2	205	February 27, 2024
Skipping risk assessment	4	298	February 11, 2024
Can we bypass confirmatory testing of DP based on Theoretical Calc. of NDSRI's	5	428	February 7, 2024
QSAR Toolbox - Free software. Any experience?	17	1095	January 24, 2024
Nitrosamines risk assessment and batch results	4	327	January 23, 2024
Duplex Sequencing - Future of mutagenicity assessment	3	448	January 23, 2024
⚖️ Risk assessment not strong enough, specifically on related impurities containing secondary amine	11	833	January 19, 2024
Bard responds to Nitrosamine Risk Assessment scheme	1	474	January 16, 2024
Potential Event with USP & Health Authorities	8	631	February 2, 2024
QSAR Models - Ames/QSAR International Challenge Project - 21 teams from 11 countries QSAR	0	277	December 12, 2023
Nitrosamine in Azathioprine Drug_Substance_APIs	2	403	November 20, 2023
Risk analysis of nitrosamine impurities in liquid products (essences and flavors) Manufacturing , Excipients	2	360	November 14, 2023
Nitrosamine Risk Assessment for Purified Water Used in Manufacturing for Pilot Bio/Clinical Trial Batches	2	876	October 22, 2023
🖥 Berkeley Madonna Software for Nitrosation Kinetic Calculations	4	550	October 3, 2023
Nitrosamines risk assessments for Topical herbal extracts Manufacturing	1	376	September 20, 2023
Enhanced Ames Test Conditions for N-nitrosamines (Q&A Rev.16)	9	1909	September 13, 2023
Quantitation of Reactive Nitrosating Agents in Pharmaceutical Excipients for N‑Nitrosamine Risk Assessments Excipients	4	987	September 7, 2023
Forced Degradation and the NAP test	3	453	September 2, 2023
N-nitrosoamides - a horse of a different color Drug_Substance_APIs	32	3212	September 1, 2023
Potency score for protected hydroxy group	2	388	August 22, 2023
Risk Assessemento of Nitrosamines in soft capsule	6	758	August 16, 2023
On the Risk of Nitrosamine Contamination during blister packaging Packaging	2	737	August 10, 2023

Carcinogenic Potency Database - Access free

With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…